Mutations in the promoter sequence of the gene encoding a component of the enzyme telomerase have been discovered in patients with melanoma, suggesting that mutations in this regulatory region can drive tumour development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Huang, F. W. et al. Science 339, 957–959 (2013).
Horn, S. et al. Science 339, 959–961 (2013).
Pleasance, E. D. et al. Nature 463, 191–196 (2010).
Hodis, E. et al. Cell 150, 251–263 (2012).
Krauthammer, M. et al. Nature Genet. 44, 1006–1014 10.1038/ng.2359 (2012).
Harrington, L. Mutat. Res. 730, 37–42 (2012).
Ding, Z. et al. Cell 148, 896–907 (2012).
Jané-Valbuena, J. et al. Cancer Res. 70, 2075–2084 (2010).
Capper, R. et al. Genes Dev. 21, 2495–2508 (2007).
Xu, L. & Blackburn, E. H. Mol. Cell 28, 315–327 (2007).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Patton, E., Harrington, L. Trouble upstream. Nature 495, 320–321 (2013). https://doi.org/10.1038/495320a
Published:
Issue Date:
DOI: https://doi.org/10.1038/495320a
This article is cited by
-
A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Nature Reviews Clinical Oncology (2017)